Abstract:Abstract Background Second-generation resorbable magnesium scaffold (RMS) Magmaris showed favorable outcomes in clinical trials, especially regarding the incidence of scaffold thrombosis. The earlier studies reported a higher occurrence of scaffold recoil with this RMS owing to vessel constriction. This finding was shown to be more prominent in presence of underlying fibrous plaques rather than calcific and/or lipidic lesions. This suggest that sufficient radial force along with longer scaffolding time may improve the device performance. Against this background, DREAMS 3G was developed with stronger mechanical properties despite thinner struts by modifying the magnesium alloy of its predecessor. The first-in-man trial BIOMAG-I demonstrated promising results for the novel RMS with respect to clinical and angiographic outcomes at 6 months follow-up. Still, the data concerning the performance of DREAMS 3G scaffold up to 12-months are lacking. Purpose This study aims to assess the influence of the intravascular optical coherence tomography (OCT) -derived underlying plaque characteristics on mean lumen area (mm 2) in patients treated with DREAMS 3G at 6- and 12-months. Methods Patients enrolled in the BIOMAG-I trial and who underwent OCT imaging (i) at index-procedure, (ii) at 6-months and (iii) at 12-months follow-up were included in the current analysis. The acquired intravascular imaging data were evaluated every 1 mm on a quadrant basis to assess the presence of fibrous, calcific, or lipidic lesions. We calculated the proportions of each plaque feature per pullback, then assessed their correlation with the mean lumen area obtained at 6- and 12-months follow-up. In addition, we investigated the potential impact of scaffold edge dissection on the mean lumen area. Results Fifty-one patients and 52 lesions were evaluated in the current analysis. There was no significant correlation between the underlying plaque characteristic and mean lumen area at 6-months (p=0.767 for fibrous, p=0.761 for calcific, p=0.767 for lipid lesions). This trend was similar at 12 months follow-up (p=0.499 for fibrous, p=0.714 for calcific, p=0.569 for lipid lesions). Finally, the presence of edge dissection did not correlate with mean lumen area (p=0.559 and p=0.670 at 6- and 12-months follow-up, respectively). Conclusion The underlying plaque characteristics and the presence of edge dissection had no significant impact on the mean lumen area following DREAMS 3G implantation up to 12 months. These results suggest better device performance with the novel RMS irrespective of the underlying plaque characteristics.

Optimal Pre-dilatation Treatment before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis. The OPTIMIS trial

Three‐year Clinical Outcomes of the Novel Sirolimus‐eluting Bioresorbable Scaffold for the Treatment of De Novo Coronary Artery Disease: A Prospective Patient‐level Pooled Analysis of NeoVas Trials

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Comparison Of Rotational Atherectomy And Modified Balloons Prior To Drug-Eluting Stent Implantation For The Treatment Of Heavily Calcified Coronary Lesions

Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter "real-world" registry

Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy

The Short‐Term and One‐Year Clinical Outcomes in Patients with Optical Coherence Tomography‐Guided Magmaris Implantation: A Real‐World Clinical Practice

Bioresorbable magnesium scaffold in the treatment of simple coronary bifurcation lesions: The BIFSORB pilot II study

Very late Magmaris scaffold restenosis: a 6-year serial optical coherence tomography case report

Safety and efficacy of systematic lesion preparation with a novel generation scoring balloon in complex percutaneous interventions: results from a prospective registry

Biolimus-Coated Balloon in Small-Vessel Coronary Artery Disease the BIO-RISE CHINA Study

Long-Term Clinical Outcomes of Isolated Ostial Left Anterior Descending Disease Treatment: Ostial Stenting Versus Left Main Cross-Over Stenting.

Super high-pressure balloon versus scoring balloon to prepare severely calcified coronary lesions: the ISAR-CALC randomised trial

Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions

The impact of underlying plaque characteristics following the novel resorbable magnesium scaffold implantation: an intravascular OCT assessment up to 12-months

Lower revascularization rates after high-speed rotational atherectomy compared to modified balloons in calcified coronary lesions: 5-year outcomes of the randomized PREPARE-CALC trial

Twelve-months vessel healing profile following the novel resorbable magnesium scaffold implantation: an intravascular OCT analysis of the BIOMAG-I trial

5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique

Bioresorbable scaffolds vs. drug-eluting stents on short- and mid-term target lesion outcomes in patients after PCI: A systematic review and meta-analysis

Bioresorbable scaffolds vs. drug-eluting stents for patients with myocardial infarction: A systematic review and meta-analysis of randomized clinical trials

One-year clinical outcomes after unrestricted implantation of the Absorb bioresorbable scaffold (RAI registry)